Clinical Trial Update: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of apalutamide, abiraterone acetate, and prednisone in metastatic castration-resistant prostate cancer has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• PREDNISONE (Prednisone)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation | Phase 2 | Status: TERMINATED